Lim K S, Lim K J, Price A C, Orr B A, Eberhart C G, Bar E E
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
Oncogene. 2014 Aug 28;33(35):4433-41. doi: 10.1038/onc.2013.390. Epub 2013 Sep 30.
Hypoxic regions are frequent in glioblastoma (GBM), the most common type of malignant adult brain tumor, and increased levels of tumor hypoxia have been associated with worse clinical outcomes. To unmask genes important in hypoxia, we treated GBM neurospheres in hypoxia and identified monocarboxylate transporter-4 (MCT4) as one of the most upregulated genes. To investigate the clinical importance of MCT4 in GBM, we examined clinical outcomes and found that MCT4 overexpression is associated with shorter patient survival. Consistent with this, MCT4 upregulation correlated with the aggressive mesenchymal subset of GBM, and MCT4 downregulation correlated with the less aggressive G-CIMP (Glioma CpG Methylator Phenotype) subset of GBM. Immunohistochemical analysis of tissue microarrays confirmed that MCT4 protein levels were increased in high-grade as compared with lower-grade astrocytomas, further suggesting that MCT4 is a clinically relevant target. To test the requirement for MCT4 in vitro, we transduced neurospheres with lentiviruses encoding short-hairpin RNAs (shRNAs) against MCT4, resulting in growth inhibition of 50-80% under hypoxia in two lines. MCT4 knockdown was associated with a decreased percentage of cells expressing the stem-cell marker CD133 and increased apoptotic fraction. We also found that flow-sorted CD133-positive cells had almost sixfold higher MCT4 levels than CD133-negative cells, suggesting that the stem-like population might have a greater requirement for MCT4. Most importantly, MCT4 silencing also slowed GBM intracranial xenograft growth in vivo. Interestingly, whereas MCT4 is a well-characterized lactate exporter, we found that both intracellular and extracellular lactate levels did not change following MCT4 silencing, suggesting a novel lactate export-independent mechanism for growth inhibition in GBMs. To identify this potential mechanism, we performed microarray analysis on control and shMCT4-expressing neurospheres and found a dramatic reduction in the expression of multiple Hypoxia-Inducible Factor (HIF)-regulated genes following MCT4 knockdown. The overall reduction in HIF transcriptional response was further validated using a hypoxia response element (HRE)-dependent green-fluorescent protein (GFP) reporter line.
缺氧区域在胶质母细胞瘤(GBM)中很常见,GBM是成人最常见的恶性脑肿瘤类型,肿瘤缺氧水平升高与较差的临床预后相关。为了揭示在缺氧状态下重要的基因,我们在缺氧条件下处理GBM神经球,并确定单羧酸转运蛋白4(MCT4)是上调最为明显的基因之一。为了研究MCT4在GBM中的临床重要性,我们检查了临床预后,发现MCT4过表达与患者生存期缩短相关。与此一致的是,MCT4上调与GBM的侵袭性间充质亚群相关,而MCT4下调与GBM侵袭性较低的G-CIMP(胶质瘤CpG甲基化表型)亚群相关。组织微阵列的免疫组织化学分析证实,与低级别星形细胞瘤相比,高级别星形细胞瘤中MCT4蛋白水平升高,进一步表明MCT4是一个与临床相关的靶点。为了在体外测试对MCT4的需求,我们用编码针对MCT4的短发夹RNA(shRNA)的慢病毒转导神经球,导致两个细胞系在缺氧条件下生长抑制50%-80%。MCT4敲低与表达干细胞标志物CD133的细胞百分比降低和凋亡分数增加相关。我们还发现,通过流式细胞术分选的CD133阳性细胞的MCT4水平几乎是CD133阴性细胞的六倍,这表明干细胞样群体可能对MCT4有更大的需求。最重要的是,MCT4沉默也减缓了GBM颅内异种移植瘤在体内的生长。有趣的是,尽管MCT4是一种已被充分表征的乳酸转运蛋白,但我们发现MCT4沉默后细胞内和细胞外乳酸水平均未改变,这表明GBM中存在一种新的不依赖乳酸转运的生长抑制机制。为了确定这种潜在机制,我们对对照和表达shMCT4的神经球进行了微阵列分析,发现MCT4敲低后多个缺氧诱导因子(HIF)调控基因的表达显著降低。使用缺氧反应元件(HRE)依赖性绿色荧光蛋白(GFP)报告细胞系进一步验证了HIF转录反应的总体降低。